GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (STU:I9DN) » Definitions » Cyclically Adjusted Revenue per Share

Arbutus Biopharma (STU:I9DN) Cyclically Adjusted Revenue per Share : €0.23 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Arbutus Biopharma's adjusted revenue per share for the three months ended in Mar. 2024 was €0.008. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.23 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Arbutus Biopharma's average Cyclically Adjusted Revenue Growth Rate was -32.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -22.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Arbutus Biopharma was -12.50% per year. The lowest was -23.00% per year. And the median was -17.70% per year.

As of today (2024-05-26), Arbutus Biopharma's current stock price is €2.994. Arbutus Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.23. Arbutus Biopharma's Cyclically Adjusted PS Ratio of today is 13.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arbutus Biopharma was 16.21. The lowest was 1.02. And the median was 5.22.


Arbutus Biopharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted Revenue per Share Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.50 0.41 0.34 0.24

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.31 0.30 0.24 0.23

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PS Ratio falls into.



Arbutus Biopharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arbutus Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.008/131.7762*131.7762
=0.008

Current CPI (Mar. 2024) = 131.7762.

Arbutus Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.060 100.560 0.079
201409 0.153 100.428 0.201
201412 0.158 99.070 0.210
201503 0.143 99.621 0.189
201506 0.056 100.684 0.073
201509 0.071 100.392 0.093
201512 0.199 99.792 0.263
201603 0.011 100.470 0.014
201606 0.005 101.688 0.006
201609 0.013 101.861 0.017
201612 -0.003 101.863 -0.004
201703 0.004 102.862 0.005
201706 0.017 103.349 0.022
201709 0.105 104.136 0.133
201712 0.039 104.011 0.049
201803 0.021 105.290 0.026
201806 0.019 106.317 0.024
201809 0.025 106.507 0.031
201812 0.027 105.998 0.034
201903 0.011 107.251 0.014
201906 0.010 108.070 0.012
201909 0.049 108.329 0.060
201912 0.025 108.420 0.030
202003 0.020 108.902 0.024
202006 0.019 108.767 0.023
202009 0.016 109.815 0.019
202012 0.023 109.897 0.028
202103 0.019 111.754 0.022
202106 0.020 114.631 0.023
202109 0.028 115.734 0.032
202112 0.021 117.630 0.024
202203 0.077 121.301 0.084
202206 0.091 125.017 0.096
202209 0.040 125.227 0.042
202212 0.038 125.222 0.040
202303 0.039 127.348 0.040
202306 0.026 128.729 0.027
202309 0.026 129.860 0.026
202312 0.012 129.419 0.012
202403 0.008 131.776 0.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Arbutus Biopharma  (STU:I9DN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arbutus Biopharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.994/0.23
=13.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arbutus Biopharma was 16.21. The lowest was 1.02. And the median was 5.22.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Arbutus Biopharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (STU:I9DN) Business Description

Industry
Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (STU:I9DN) Headlines

No Headlines